BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 07, 2005
 |  BioCentury  |  Strategy

Ready, set, spin?

In mid-2000, Genencor International Inc. told the world that it planned to apply its protein engineering expertise to build a therapeutics business. In large part, the drive behind this transition was the slow growth of revenues from its industrial enzymes business, which clearly weren't going to move the company to the next level. But making these transitions has always been easier said than done, and with the recent news that food play Danisco A/S is buying GCOR, it's likely that the life science division - which GCOR created in December - will be spun out and recapitalized sooner rather than later.

Mark Goldsmith, senior vice president of healthcare, said that upon entering the pharmaceutical space, "the plan was to take a broad approach and invest in numerous programs so that...

Read the full 642 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >